**Supplementary Table S1.** Potential *EGFR* mAb resistance mutations beyond *KRAS* mutations

|  |  |
| --- | --- |
| **Gene** | **Frequency** |
| *BRAF* mutations | 12.1% |
| *ERBB2* mutations/amplifications | 5.0% |
| *EGFR* mutations (ECD) | 4.2% |
| *MET* amplifications/fusions | 3.5% |
| *RET* fusions | 1.1% |
| *ALK* fusions | 0.5% |